New cocktail aims to stop bile duct cancer recurrence
NCT ID NCT07679399
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This phase II trial tests whether a combination of durvalumab (an immunotherapy), chemotherapy (GEMOX or GC), followed by lenvatinib (a targeted therapy) can prevent biliary tract cancer from coming back after surgery. About 222 adults with bile duct or gallbladder cancer will be randomly assigned to receive either this combination or standard capecitabine chemotherapy. The main goal is to see if the combination improves the number of patients who remain cancer-free one year after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab, gemcitabine, oxaliplatin, cisplatin, lenvatinib, capecitabine
- What this could lead to
- If successful, this combination could offer a more effective way to prevent biliary tract cancer from returning after surgery.
- What could go wrong
- This is a phase II trial, so results are preliminary. The combination may cause more side effects than standard therapy and may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing, 100730
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Liver cancer registry aims to uncover new biomarkers from thousands of patients
- Triple-Drug cocktail targets Hard-to-Treat biliary cancers